Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II first-line lorlatinib monotherapy in advanced ALK-positive non-small cell lung cancer
ChiCTR2300077474Phase 2Recruiting
- Sponsor
- Guangdong Provincial People's Hospital
- Start
- Aug 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of lorlatinib in non-small cell lung cancer (NSCLC) and ALK-positive non-small cell lung cancer (2 cohorts), sponsored by Guangdong Provincial People's Hospital. Primary endpoints: Progression-free survival and Drug resistance mechanism. Started Aug 2023; status: recruiting.
02
Drugs
lorlatinib
03
Conditions
non-small cell lung cancer (NSCLC)ALK-positive non-small cell lung cancer
Beyond the preview
Go deeper on ChiCTR2300077474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300077474.